Medical News

RSS

New implantable sensor to continuously monitor tissue glucose

Bioengineers at the University of California, San Diego and GlySens Incorporated have developed an implantable glucose sensor and wireless telemetry system that continuously monitors tissue glucose and transmits the information to an external receiver. The paper, published in the July 28, 2010 issue of the journal Science Translational Medicine, describes the use of this glucose-sensing device as an implant in animals for over one year. After human clinical trials and FDA approval, the device may be useful to people with diabetes as an alternative to finger sticking and short-term, needle-like glucose sensors that have to be replaced every three to seven days.

29 Jul 2010

Mylan second-quarter adjusted diluted EPS increases to $0.37

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

29 Jul 2010

Innovative campaign to increase awareness, use of female condom

The Washington AIDS Partnership today announced that the second phase of an innovative campaign to increase awareness and use of the female condom as a tool for HIV prevention will launch across the District this week.

29 Jul 2010

NDS Surgical Imaging introduces ConnectOR G2 visualization and informatics platform

NDS Surgical Imaging (NDSsi) today launched its next-generation visualization and informatics platform—the ConnectOR G2—with production units now shipping to customers. Based on the NDSsi technology vision of Medical Visualization Informatics (MVI), ConnectOR G2 medical-grade products are leading the industry in procedural efficacy by offering the unique ability to connect the realms of PACS imaging, surgical video and medical informatics.

29 Jul 2010

New test to predict suitable treatment for chronic myeloid leukemia patients

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).

29 Jul 2010

Chemed second-quarter consolidated revenues increase 6.7% to $315.0 million

Chemed Corporation, which operates VITAS Healthcare Corporation, the nation's largest provider of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2010, versus the comparable prior-year period.

29 Jul 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

REM sleep behavior disorder may later lead to neurologic disorders

A new study shows that a sleep disorder may be a sign of dementia or Parkinson's disease up to 50 years before the disorders are diagnosed. The research is published in the July 28, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

29 Jul 2010

China PharmaHub to close Merger Agreement with World Wide Relics in August 2010

China PharmaHub Corp., a pharmaceutical HUB between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, announced today that it has entered into a Merger Agreement with World Wide Relics, Inc.. The merger is expected to close in August 2010.

29 Jul 2010

Use of nanomaterials in construction poses potential environmental and health risks

Nanomaterials are poised for widespread use in the construction industry, where they can offer significant advantages for a variety of applications ranging from making more durable concrete to self-cleaning windows. But widespread use in building materials comes with potential environmental and health risks when those materials are thrown away. Those are the conclusions of a new study published by Rice University engineering researchers this month in ACS Nano.

29 Jul 2010

Senate Subcommittee approves HHS funding bill, other health care bills readied

CongressDaily: The Senate Labor-Health and Human Services Appropriations Subcommittee approved a draft funding bill Tuesday for HHS, "moving a bill that would provide $170 billion in discretionary spending to related federal agencies, nearly $1 billion under the president's request." The bill gives $732 billion to the Department of Health and Human Services, $306 million more than the administration requested. "The House Labor-HHS Appropriations Subcommittee gave the health agency a similar boost in funding."

29 Jul 2010

Encision’s AEM system recognized as technology to eliminate visceral burns

Encision Inc, a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, recognized as a technology to eliminate visceral burns during monopolar electrical surgery.

29 Jul 2010

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

29 Jul 2010

Genetic interaction with diet causes variations in metabolic traits

Ever notice some people seem to eat anything they want and never gain a pound, while others seem to gain weight just by looking at fattening foods. You may be seeing things correctly after all. According to research published in the July 2010 issue of Genetics, this may have a biological cause. Using fruit flies, researchers have found that genes interacting with diet, rather than diet alone, are the main cause of variation in metabolic traits, such as body weight. This helps explain why some diets work better for some people than others, and suggests that future diets should be tailored to an individual's genes rather than to physical appearance.

29 Jul 2010

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

LeMaitre Vascular, Inc., a provider of peripheral vascular devices and implants, today announced Q2 2010 financial results. The Company posted record quarterly sales of $14.2mm and record quarterly operating income of $2.0mm. The Company also increased its share repurchase program to $5mm and raised its sales and operating income guidance for 2010.

29 Jul 2010

Nanotechnology approaches to solve major problems on global scale: Report

Nanotechnology refers to a broad range of tools, techniques and applications that simply involve particles on the approximate size scale of a few to hundreds of nanometers in diameter. Particles of this size have some unique physicochemical and surface properties that lend themselves to novel uses. Indeed, advocates of nanotechnology suggest that this area of research could contribute to solutions for some of the major problems we face on the global scale such as ensuring a supply of safe drinking water for a growing population, as well as addressing issues in medicine, energy, and agriculture.

29 Jul 2010

Mapping NTDs is critical for controlling, treating diseases

Mapping neglected tropical diseases (NTDs) is vital for efforts to control and treat diseases, write the authors of an editorial published Tuesday in PLoS Neglected Tropical Diseases, ANI/Sindh Today reports (7/28).

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Odyssey Healthcare second-quarter net patient service revenue increases 3.5% to $176.2 million

Odyssey HealthCare, Inc., one of the largest providers of hospice care in the United States, today announced financial results for the three and six months ended June 30, 2010.

29 Jul 2010